dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2015-12-07T15:37:22Z
dc.date.available2015-12-07T15:37:22Z
dc.date.created2015-12-07T15:37:22Z
dc.date.issued2015-09-01
dc.identifierLife Sciences, v. 136, p. 60-66, 2015.
dc.identifier1879-0631
dc.identifierhttp://hdl.handle.net/11449/131548
dc.identifier10.1016/j.lfs.2015.06.012
dc.identifier1697547325096457
dc.identifier26141991
dc.description.abstractThe etiopathogenesis of inflammatory bowel disease (IBD) is unclear and further understanding of the mechanisms that regulate intestinal barrier integrity and function could give insight into its pathophysiology and mode of action of current drugs used to treat human IBD. Therefore, we investigated how intestinal inflammation affects Map kinase gene expression in rats, and if current intestinal anti-inflammatory drugs (sulphasalazine, prednisolone and azathioprine) act on these expressions. Macroscopic parameters of lesion, biochemical markers (myeloperoxidase, alkaline phosphatase and glutathione), gene expression of 13Map kinases, and histologic evaluations (optic, electronic scanning and transmission microscopy) were performed in rats with colonic inflammation induced by trinitrobenzenesulphonic (TNBS) acid. The colonic inflammation was characterized by a significant increase in the expression of Mapk1, Mapk3 and Mapk9 accompanied by a significant reduction in the expression ofMapk6. Alterations inMapk expression induced by TNBS were differentially counteracted after treatment with sulphasalazine, prednisolone and azathioprine. Protective effects were also related to the significant reduction of oxidative stress, which was related to increase Mapk1/3 expressions, which were reduced after pharmacological treatment. Mapk1, Mapk3,Mapk6 and Mapk9 gene expressionswere affected by colonic inflammation induced by TNBS in rats and counteracted by sulphasalazine, prednisolone and azathioprine treatments, suggesting that these genes participate in the pharmacological response produced for these drugs.
dc.languageeng
dc.publisherElsevier B. V.
dc.relationLife Sciences
dc.rightsAcesso restrito
dc.sourcePubMed
dc.subjectInflammatory bowel disease
dc.subjectIntestinal anti-inflammatory drugs
dc.subjectIntestinal inflammation
dc.subjectMap kinases
dc.titleExperimental evidence of MAP kinase gene expression on the response of intestinal anti-inflammatory drugs
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución